BioCentury's latest roundup of biopharma regulatory news includes early access in the U.K. for an Alnylam RNAi; plus setbacks at FDA for Verrica, CytoDyn, and updates from J&amp;J and Roche $ALNY $VRCA $CYDY $JNJ $ROG https://t.co/LEFYtyhrxW